Patents by Inventor Adam Judge

Adam Judge has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12251470
    Abstract: The invention provides certain specific lipid nanoparticles comprising: (a) one or more nucleic acid molecules; (b) cholesterol; (c) DSPC; (d) PEG-C-DMA; and (e) a cationic lipid; and pharmaceutical compositions comprising the lipid nanoparticles. The lipid nanoparticles and pharmaceutical compositions are particularly useful for delivering a nucleic acid such as siRNA or mRNA to a patient (e.g. a human) or to a cell.
    Type: Grant
    Filed: November 8, 2019
    Date of Patent: March 18, 2025
    Assignee: ARBUTUS BIOPHARMA CORPORATION
    Inventors: James Heyes, Adam Judge, Kieu Mong Lam, Lorne Ralph Palmer, Petra Schreiner
  • Publication number: 20240316206
    Abstract: The present invention provides novel, serum-stable lipid particles comprising one or more active agents or therapeutic agents, methods of making the lipid particles, and methods of delivering and/or administering the lipid particles. More particularly, the present invention provides serum-stable nucleic acid-lipid particles (SNALP) comprising a nucleic acid (e.g., one or more interfering RNA molecules), methods of making the SNALP, and methods of delivering and/or administering the SNALP (e.g., for the treatment of cancer). In particular embodiments, the present invention provides tumor-directed lipid particles that preferentially target solid tumors. The tumor-directed formulations of the present invention are capable of preferentially delivering a payload such as a nucleic acid to cells of solid tumors compared to non-cancerous cells.
    Type: Application
    Filed: April 25, 2024
    Publication date: September 26, 2024
    Applicant: ARBUTUS BIOPHARMA CORPORATION
    Inventors: Ed Yaworski, Stephen Reid, James Heyes, Adam Judge, Ian MacLachlan
  • Patent number: 12043833
    Abstract: The invention provides certain nucleic acids (e.g., double stranded siRNA molecules), as well as conjugates that comprise a targeting moiety, a double stranded siRNA, and optional linking groups. Certain embodiments also provide synthetic methods useful for preparing the conjugates. The conjugates are useful to target therapeutic double stranded siRNA to the liver and to treat liver diseases including hepatitis (e.g. hepatitis B and hepatitis D).
    Type: Grant
    Filed: June 30, 2022
    Date of Patent: July 23, 2024
    Assignee: ARBUTUS BIOPHARMA CORPORATION
    Inventors: James Heyes, Richard J. Holland, Adam Judge, Amy C. H. Lee, Alan D. Martin, Nicholas Michael Snead, Emily P. Thi, Mark Wood, Xin Ye
  • Publication number: 20240207462
    Abstract: Described herein are immunoconjugates comprising an: a) antigen binding region; b) an immunoglobulin heavy chain constant region; and c) a radioisotope chelating agent; wherein the molecular weight of said immunoconjugate is between 60 and 110 kDa. The immunoconjugates can be used to deliver alpha and beta emitters for the treatment of tumors or cancer.
    Type: Application
    Filed: August 17, 2023
    Publication date: June 27, 2024
    Inventors: Adam JUDGE, Michael ABRAMS, Alexander Laurence MANDEL, Raja Solomon VISWAS
  • Patent number: 12016929
    Abstract: The present invention provides novel, serum-stable lipid particles comprising one or more active agents or therapeutic agents, methods of making the lipid particles, and methods of delivering and/or administering the lipid particles. More particularly, the present invention provides serum-stable nucleic acid-lipid particles (SNALP) comprising a nucleic acid (e.g., one or more interfering RNA molecules), methods of making the SNALP, and methods of delivering and/or administering the SNALP (e.g., for the treatment of cancer). In particular embodiments, the present invention provides tumor-directed lipid particles that preferentially target solid tumors. The tumor-directed formulations of the present invention are capable of preferentially delivering a payload such as a nucleic acid to cells of solid tumors compared to non-cancerous cells.
    Type: Grant
    Filed: January 12, 2024
    Date of Patent: June 25, 2024
    Assignee: ARBUTUS BIOPHARMA CORPORATION
    Inventors: Ed Yaworski, Stephen Reid, James Heyes, Adam Judge, Ian MacLachlan
  • Publication number: 20240148875
    Abstract: The present invention provides novel, serum-stable lipid particles comprising one or more active agents or therapeutic agents, methods of making the lipid particles, and methods of delivering and/or administering the lipid particles. More particularly, the present invention provides serum-stable nucleic acid-lipid particles (SNALP) comprising a nucleic acid (e.g., one or more interfering RNA molecules), methods of making the SNALP, and methods of delivering and/or administering the SNALP (e.g., for the treatment of cancer). In particular embodiments, the present invention provides tumor-directed lipid particles that preferentially target solid tumors. The tumor-directed formulations of the present invention are capable of preferentially delivering a payload such as a nucleic acid to cells of solid tumors compared to non-cancerous cells.
    Type: Application
    Filed: January 12, 2024
    Publication date: May 9, 2024
    Applicant: ARBUTUS BIOPHARMA CORPORATION
    Inventors: Ed Yaworski, Stephen Reid, James Heyes, Adam Judge, Ian MacLachlan
  • Publication number: 20240100166
    Abstract: The present invention provides novel, serum-stable lipid particles comprising one or more active agents or therapeutic agents, methods of making the lipid particles, and methods of delivering and/or administering the lipid particles. More particularly, the present invention provides serum-stable nucleic acid-lipid particles (SNALP) comprising a nucleic acid (e.g., one or more interfering RNA molecules), methods of making the SNALP, and methods of delivering and/or administering the SNALP (e.g., for the treatment of cancer). In particular embodiments, the present invention provides tumor-directed lipid particles that preferentially target solid tumors. The tumor-directed formulations of the present invention are capable of preferentially delivering a payload such as a nucleic acid to cells of solid tumors compared to non-cancerous cells.
    Type: Application
    Filed: September 5, 2023
    Publication date: March 28, 2024
    Applicant: ARBUTUS BIOPHARMA CORPORATION
    Inventors: Ed Yaworski, Stephen Reid, James Heyes, Adam Judge, Ian MacLachlan
  • Patent number: 11786598
    Abstract: The present invention provides novel, serum-stable lipid particles comprising one or more active agents or therapeutic agents, methods of making the lipid particles, and methods of delivering and/or administering the lipid particles. More particularly, the present invention provides serum-stable nucleic acid-lipid particles (SNALP) comprising a nucleic acid (e.g., one or more interfering RNA molecules), methods of making the SNALP, and methods of delivering and/or administering the SNALP (e.g., for the treatment of cancer). In particular embodiments, the present invention provides tumor-directed lipid particles that preferentially target solid tumors. The tumor-directed formulations of the present invention are capable of preferentially delivering a payload such as a nucleic acid to cells of solid tumors compared to non-cancerous cells.
    Type: Grant
    Filed: July 25, 2022
    Date of Patent: October 17, 2023
    Assignee: ARBUTUS BIOPHARMA CORPORATION
    Inventors: Ed Yaworski, Stephen Reid, James Heyes, Adam Judge, Ian MacLachlan
  • Publication number: 20230248831
    Abstract: The present invention provides novel, serum-stable lipid particles comprising one or more active agents or therapeutic agents, methods of making the lipid particles, and methods of delivering and/or administering the lipid particles. More particularly, the present invention provides serum-stable nucleic acid-lipid particles (SNALP) comprising a nucleic acid (e.g., one or more interfering RNA molecules), methods of making the SNALP, and methods of delivering and/or administering the SNALP (e.g., for the treatment of cancer). In particular embodiments, the present invention provides tumor-directed lipid particles that preferentially target solid tumors. The tumor-directed formulations of the present invention are capable of preferentially delivering a payload such as a nucleic acid to cells of solid tumors compared to non-cancerous cells.
    Type: Application
    Filed: July 25, 2022
    Publication date: August 10, 2023
    Applicant: ARBUTUS BIOPHARMA CORPORATION
    Inventors: Ed Yaworski, Stephen Reid, James Heyes, Adam Judge, Ian MacLachlan
  • Publication number: 20230110295
    Abstract: The invention provides certain nucleic acids (e.g., double stranded siRNA molecules), as well as conjugates that comprise a targeting moiety, a double stranded siRNA, and optional linking groups. Certain embodiments also provide synthetic methods useful for preparing the conjugates. The conjugates are useful to target therapeutic double stranded siRNA to the liver and to treat liver diseases including hepatitis (e.g. hepatitis B and hepatitis D).
    Type: Application
    Filed: June 30, 2022
    Publication date: April 13, 2023
    Applicant: ARBUTUS BIOPHARMA CORPORATION
    Inventors: James HEYES, Richard J. HOLLAND, Adam JUDGE, Amy C. H. LEE, Alan D. MARTIN, Nicholas Michael SNEAD, Emily P. THI, Mark WOOD, Xin YE
  • Patent number: 11446383
    Abstract: The present invention provides novel, serum-stable lipid particles comprising one or more active agents or therapeutic agents, methods of making the lipid particles, and methods of delivering and/or administering the lipid particles. More particularly, the present invention provides serum-stable nucleic acid-lipid particles (SNALP) comprising a nucleic acid (e.g., one or more interfering RNA molecules), methods of making the SNALP, and methods of delivering and/or administering the SNALP (e.g., for the treatment of cancer). In particular embodiments, the present invention provides tumor-directed lipid particles that preferentially target solid tumors. The tumor-directed formulations of the present invention are capable of preferentially delivering a payload such as a nucleic acid to cells of solid tumors compared to non-cancerous cells.
    Type: Grant
    Filed: August 22, 2018
    Date of Patent: September 20, 2022
    Assignee: ARBUTUS BIOPHARMA CORPORATION
    Inventors: Ed Yaworski, Stephen Reid, James Heyes, Adam Judge, Ian MacLachlan
  • Patent number: 11427823
    Abstract: The invention provides certain nucleic acids (e.g., double stranded siRNA molecules), as well as conjugates that comprise a targeting moiety, a double stranded siRNA, and optional linking groups. Certain embodiments also provide synthetic methods useful for preparing the conjugates. The conjugates are useful to target therapeutic double stranded siRNA to the liver and to treat liver diseases including hepatitis (e.g. hepatitis B and hepatitis D).
    Type: Grant
    Filed: April 10, 2018
    Date of Patent: August 30, 2022
    Assignee: ARBUTUS BIOPHARMA CORPORATION
    Inventors: James Heyes, Richard J. Holland, Adam Judge, Amy C. H. Lee, Alan D. Martin, Nicholas Michael Snead, Emily P. Thi, Mark Wood, Xin Ye
  • Publication number: 20220168222
    Abstract: The invention provides lipid nanoparticles and formulations containing lipid nanoparticles.
    Type: Application
    Filed: April 24, 2020
    Publication date: June 2, 2022
    Applicant: GENEVANT SCIENCES GMBH
    Inventors: James HEYES, Adam JUDGE, Kieu Mong LAM, Alan D. MARTIN
  • Publication number: 20220160899
    Abstract: The present invention provides compositions comprising nucleic acid molecules, such as mRNA molecules, encapsulated within lipid particles. The compositions are useful, for example, to introduce the mRNA molecules into a human subject where they are translated to produce a polypeptide that functions to ameliorate one or more symptoms of a disease.
    Type: Application
    Filed: November 1, 2021
    Publication date: May 26, 2022
    Applicant: ARBUTUS BIOPHARMA CORPORATION
    Inventors: Michael J. ABRAMS, James HEYES, Adam JUDGE, Kieu Mong LAM, Lorne Ralph PALMER, Stephen P. REID, Edward D. YAWORSKI
  • Publication number: 20220031847
    Abstract: The invention provides methods and compositions for delivering a nucleic acid to a cell or the cytosol of the target cell. The method includes contacting the cell with, 1) a membrane-destabilizing polymer; and 2) a nucleic acid conjugate. The nucleic acid conjugate includes a targeting ligand bound to an optional linker and a nucleic acid.
    Type: Application
    Filed: November 4, 2019
    Publication date: February 3, 2022
    Applicant: GENEVANT SCIENCES GMBH
    Inventors: James HEYES, Richard J. HOLLAND, Adam JUDGE, Kieu Mong LAM
  • Publication number: 20220000778
    Abstract: The invention provides certain specific lipid nanoparticles comprising: (a) one or more nucleic acid molecules; (b) cholesterol; (c) DSPC; (d) PEG-C-DMA; and (e) a cationic lipid; and pharmaceutical compositions comprising the lipid nanoparticles. The lipid nanoparticles and pharmaceutical compositions are particularly useful for delivering a nucleic acid such as siRNA or mRNA to a patient (e.g. a human) or to a cell.
    Type: Application
    Filed: November 8, 2019
    Publication date: January 6, 2022
    Applicant: ARBUTUS BIOPHARMA CORPORATION
    Inventors: James HEYES, Adam JUDGE, Kieu Mong LAM, Lorne Ralph PALMER, Petra SCHREINER
  • Patent number: 11191849
    Abstract: The present invention provides compositions comprising nucleic acid molecules, such as mRNA molecules, encapsulated within lipid particles. The compositions are useful, for example, to introduce the mRNA molecules into a human subject where they are translated to produce a polypeptide that functions to ameliorate one or more symptoms of a disease.
    Type: Grant
    Filed: June 30, 2017
    Date of Patent: December 7, 2021
    Assignee: ARBUTUS BIOPHARMA CORPORATION
    Inventors: Michael J. Abrams, James Heyes, Adam Judge, Kieu Mong Lam, Lorne Ralph Palmer, Stephen P. Reid, Edward D. Yaworski
  • Publication number: 20200407724
    Abstract: The invention provides certain nucleic acids (e.g., double stranded siRNA molecules), as well as conjugates that comprise a targeting moiety, a double stranded siRNA, and optional linking groups. Certain embodiments also provide synthetic methods useful for preparing the conjugates. The conjugates are useful to target therapeutic double stranded siRNA to the liver and to treat liver diseases including hepatitis (e.g. hepatitis B and hepatitis D).
    Type: Application
    Filed: April 10, 2018
    Publication date: December 31, 2020
    Applicant: ARBUTUS BIOPHARMA CORPORATION
    Inventors: James HEYES, Richard J. HOLLAND, Adam JUDGE, Amy C. H. LEE, Alan D. MARTIN, Nicholas Michael SNEAD, Emily P. THI, Mark WOOD, Xin YE
  • Publication number: 20190240339
    Abstract: The present invention provides novel, serum-stable lipid particles comprising one or more active agents or therapeutic agents, methods of making the lipid particles, and methods of delivering and/or administering the lipid particles. More particularly, the present invention provides serum-stable nucleic acid-lipid particles (SNALP) comprising a nucleic acid (e.g., one or more interfering RNA molecules), methods of making the SNALP, and methods of delivering and/or administering the SNALP (e.g., for the treatment of cancer). In particular embodiments, the present invention provides tumor-directed lipid particles that preferentially target solid tumors. The tumor-directed formulations of the present invention are capable of preferentially delivering a payload such as a nucleic acid to cells of solid tumors compared to non-cancerous cells.
    Type: Application
    Filed: August 22, 2018
    Publication date: August 8, 2019
    Inventors: Ed Yaworski, Stephen Reid, James Heyes, Adam Judge, Ian MacLachlan
  • Publication number: 20190240354
    Abstract: The present invention provides compositions comprising nucleic acid molecules, such as mRNA molecules, encapsulated within lipid particles. The compositions are useful, for example, to introduce the mRNA molecules into a human subject where they are translated to produce a polypeptide that functions to ameliorate one or more symptoms of a disease.
    Type: Application
    Filed: June 30, 2017
    Publication date: August 8, 2019
    Applicant: ARBUTUS BIOPHARMA CORPORATION
    Inventors: Michael J. ABRAMS, James HEYES, Adam JUDGE, Kieu Mong LAM, Lorne Ralph PALMER, Stephen P. REID, Edward D. YAWORSKI